[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"functional-dysphonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:functional-dysphonia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100641471","assessment-of-the-efficacy-of-a-highly-standardized-ginger-and-perilla-nutraceutical-dispepril-in-improving-gastric-and-intestinal-symptoms-in-patients-with-functional-dyspepsia-100641471",false,"NCT07655219","Assessment of the Efficacy of a Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia","Assessment of the Efficacy of a Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia: A Multicenter, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n* Male or female participants aged 18 to 65 years\n* Diagnosis of functional dyspepsia according to Rome IV criteria\n* Willingness and ability to provide written informed consent\n* Ability to follow study product administration instructions\n* Ability to attend scheduled study visits\n\nExclusion Criteria:\n\n* Gastrectomy\n* Cancer\n* Use of NSAIDs, cholagogues, or tricyclic antidepressants within 30 days prior to enrollment\n* Helicobacter pylori positivity\n* Alcoholism or other substance abuse\n* Hepatic disease\n* Renal disease\n* History of hypersensitivity to formulation active ingredients or excipients\n* Pregnancy or breastfeeding\n* Participation in another clinical trial or completion of another clinical trial within 1 month prior to enrollment\n* Refusal or inability to provide informed consent","ALL","18 Years","65 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","This multicenter, prospective, randomized, controlled clinical trial aims to evaluate the efficacy of a nutraceutical treatment containing highly standardized extracts of ginger (Zingiber officinale) and perilla (Perilla frutescens) (Dispepril®, Pharmextracta S.p.A. Pontenure, Italy) in improving gastric and intestinal symptoms in adults with functional dyspepsia. The study will assess the non-inferiority of Dispepril® compared with standard proton pump inhibitor (PPI) therapy in reducing postprandial distress symptoms. Participants will be randomized in a 2:1:1 ratio to receive Dispepril® alone, Dispepril® plus half-dose PPI, or full-dose PPI for 14 days. Efficacy will be assessed using the Leuven Postprandial Distress Scale (LPDS), together with evaluations of treatment tolerability, adherence, and adverse events.",[27],"Functional Dysphonia","NOT_YET_RECRUITING","2026-06-15",{"date":31,"type":32},"2026-06-17","ACTUAL",{"date":34,"type":21},"2026-06-22",{"date":36,"type":21},"2026-11-30",{"name":38,"class":39},"Liaquat University of Medical & Health Sciences","OTHER",4,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100581936","management-of-non-organic-dysphonia-in-adults-100581936","NCT06856785","Management of Non-Organic Dysphonia in Adults.","Resonance Tube Voice Therapy Versus Smith Accent Therapy in The Management of Non-Organic Dysphonia in Adults","Inclusion Criteria:\n\n* Patients diagnosed with non-organic functional dysphonia with or without Minimally Associated Pathological lesions and referred for voice therapy. The diagnosis was based on the results of the routine clinical assessment of cases of voice disorders by a phoniatrician in the voice clinic.\n* Patients 'ages between 15 - 60 years old.\n* Native speakers of Arabic.\n* Language comprehension adequate for the task.\n\nExclusion Criteria:\n\n* Patients with organic voice disorders.\n* Patients with aphonia or Phon asthenia.\n* Females within the week of their menstrual cycle or menstruating at the time of data collection to control for the possible hormonal effects or premenstrual water retention on voice quality.\n* History of severe respiratory allergies, thyroid pathologies, neuro-motor impairment, hearing impairment, psychiatric problems and physically limiting diseases that might interfere with study completion.\n* Those on any regular medication that might affect voice quality.\n* Speech disorders.\n* Cigarette smoking, alcohol, or drug abuse for the past 5 years.\n* Patients with previous micro laryngeal surgery.\n* Patients with gastrointestinal reflux disease.",true,"15 Years","60 Years",{"count":52,"type":21},60,[24],"The purpose of this study is to determine the effect of a semi-occluded vocal tract training program, \"Resonant Tube Therapy,\" versus the \"Traditional Smith-accent Method\" on the quality of voice in patients with Non-Organic \"Functional\" dysphonia.",[27,56,57],"Resonance Tube Voice Therapy","Smith Accent Method Therapy","RECRUITING","2025-03-02",{"date":61,"type":32},"2025-03-04",{"date":63,"type":21},"2025-03",{"date":65,"type":21},"2025-09",{"name":67,"class":39},"Sohag University",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":68},"100363607","safety-and-efficacy-of-fecal-microbiota-transplantation-100363607","NCT04014413","Safety and Efficacy of Fecal Microbiota Transplantation","Safety and Efficacy of Fecal Microbiota Transplantation: A Pilot Study","Inclusion Criteria:\n\nConfirmed diagnosis of any of the following diseases:\n\n* Crohn's disease\n* Ulcerative colitis\n* Celiac disease\n* Irritable bowel syndrome\n* Functional dyspepsia\n* Constipation\n* Antibiotic-associated diarrhea or any antibiotic- associated complications\u002Fsymptoms\n* Metabolic syndrome such as diabetes mellitus and obesity\n* Multidrug-resistant infection\n* Hepatic encephalopathy\n* Multiple sclerosis\n* Pseudo-obstruction\n* Carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection\n* Multiple organ dysfunction\n* Dysbiotic bowel syndrome\n* MRSA enteritis\n* Pseudomembranous enteritis\n* Alopecia, autism\n* Graft-versus-host disease\n* Idiopathic thrombocytopenic purpura (ITP)\n* Atopy or allergy\n* Liver disease such as Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH)\n* Alcohol dependence\n* Psoriatic arthropathy that has suboptimal control of disease despite standard treatment.\n\nExclusion Criteria:\n\n* Known contraindication to all FMT infusion method such as nasoduodenal tube insertion, oesophago-gastro-duodenoscopy (OGD), enteroscopy, colonoscopy and enema\n* Any conditions that may render the efficacy of FMT or at the discretion of the investigators\n* Current pregnancy",{"count":77,"type":21},450,[24],"The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease states. Fecal microbiota transplantation (FMT), defined as infusion of feces from healthy donors to affected subjects, is a method to restore a balanced gut microbiota and has attracted great interest in recent years due to its efficacy and ease of use. FMT is now recommended as the most effective therapy for CDI not responding to standard therapies.\n\nRecent studies have suggested that dysbiosis is associated with a variety of disorders, and that FMT could be a useful treatment. Randomized controlled trial has been conducted in a number of disorders and shown positive results, including alcoholic hepatitis, Crohn's disease (CD), ulcerative colitis (UC), pouchitis, irritable bowel syndrome (IBS), hepatic encephalopathy and metabolic syndrome. Case series\u002Freports and pilot studies has shown positive results in other disorders including Celiac disease, functional dyspepsia, constipation, metabolic syndrome such as diabetes mellitus, multidrug-resistant, hepatic encephalopathy, multiple sclerosis, pseudo-obstruction, carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection, radiation-induced toxicity, multiple organ dysfunction, dysbiotic bowel syndrome, MRSA enteritis, Pseudomembranous enteritis, idiopathic thrombocytopenic purpura (ITP), and atopy.\n\nDespite FMT appears to be relatively safe and efficacious in treating a wide range of disease, its safety and efficacy in a usual clinical setting is unknown. More data is required to confirm safety and efficacy of FMT. Therefore, the investigators aim to conduct a pilot study to investigate the efficacy and safety of FMT in a variety of dysbiosis-associated disorder.",[81,82,83,84,27,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106],"Crohn Disease","Ulcerative Colitis","Celiac Disease","Irritable Bowel Syndrome","Constipation","Clostridium Difficile Infection","Diabetes Mellitus","Obesity","Multidrug -Resistant Infection","Hepatic Encephalopathy","Multiple Sclerosis","Pseudo-Obstruction","Carbapenem-Resistant Enterobacteriaceae Infection","Vancomycin Resistant Enterococci Infection","Multiple Organ Dysfunction Syndrome","Dysbiotic Bowel Syndrome","MRSA Enteritis","Pseudomembranous Enterocolitis","Alopecia","Autism","Graft-versus-host Disease","Idiopathic Thrombocytopenic Purpura","Atopy or Allergy","Liver Disease","Alcohol Dependence","Psoriatic Arthropathy","2024-08-21",{"date":109,"type":32},"2024-08-22",{"date":111,"type":32},"2019-07-15",{"date":113,"type":21},"2030-10-31",{"name":115,"class":39},"Chinese University of Hong Kong"]